C

Contineum Therapeutics
D

CTNM

11.610
USD
-1.47
(-11.24%)
مغلق
حجم التداول
34,247
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
338,808,953
المقالات

العنوان: Contineum Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.